TY - JOUR
T1 - Musculoskeletal disorders in type 1 diabetes
T2 - Clinical phenotyping and associations with quality of life and glucose control - The French SFDT1 cohort study
AU - Topalian, Noémie
AU - Picard, Sylvie
AU - Riveline, Jean Pierre
AU - Canha, Dulce
AU - Julla, Jean Baptiste
AU - Lablanche, Sandrine
AU - Salle, Laurence
AU - Sonnet, Emmanuel
AU - Berot, Aurélie
AU - Gouet, Didier
AU - Bilariki, Kalliopi
AU - Amouyal, Chloé
AU - Marchand, Lucien
AU - Borot, Sophie
AU - Chevalier, Nicolas
AU - Banu, Isabela
AU - Sokol, Emmanuelle
AU - Cosson, Emmanuel
AU - Fagherazzi, Guy
AU - Aguayo, Gloria
N1 - Funding:
JPR is an advisory panel member for Sanofi Aventis MSD, Eli Lilly,
Novo Nordisk, AstraZeneca, Abbott, Dexcom, Alphadiab and Medtronic,
and has received research funding from Abbott, Air Liquide Sant´e In-
ternational, Sanofi-Aventis and Novo Nordisk.
SP declares no conflict of interest directly related to this article.
Outside the submitted work she received speaker and/or consulting
honoraria from Abbott, Air Liquide, Asdia, Dexcom, Insulet, Isis Dia-
betes, Lifescan, Lilly, Medtronic, Novo Nordisk, Orkyn, Roche Diabetes
Care, Sanofi, VitalAire.
JBJ has received consulting fees from Sanofi and lecture fees from Eli
Lilly, Novo Nordisk, and Sanofi.
GF has provided advisory/speaking services for and/or has received
research grants and/or speaker honoraria from MSD, MSDAvenir, Eli
Lilly, Roche Diabetes Care, AstraZeneca, Danone Research, Diabeloop,
Bristol Myers Squibb, L’Or´eal R&D, Abbvie Pharmaceutical, Pfizer,
Vitalaire and Akuity Care.
Publisher Copyright:
© 2025 Elsevier Masson SAS
PY - 2025/7
Y1 - 2025/7
N2 - Background: Musculoskeletal disorders (MSDs) are common, but overlooked, complications of type 1 diabetes mellitus (T1DM). This study aims to describe MSD phenotypes (clinical, lifestyle, socio-economic) in adults with T1DM. Methods: We analyzed adult participants in the SFDT1 cohort study. We assessed the following MSDs: stress fractures, non-traumatic upper-limb disorders, and entrapment syndromes. We performed a cross-sectional analysis of the association between MSDs and various factors. After applying multiple imputations for missing data, we computed logistic regression models with progressive adjustments on confounding factors. Results: Of 1832 participants (53 % men, median age 38 (IQR 22) years), 34 % reported at least one personal history of MSD: 8 % for stress fractures, 24 % for upper-limb disorders and 15 % for entrapment syndromes. A higher prevalence of MSDs was found in women, with aging and with diabetes duration. In a fully adjusted model, we observed a positive association between current smoking (OR [95 %CI] = 1.50 [1.14;1.97]), non-excessive alcohol consumption (1.45 [1.14;1.85]), neuropathy (1.70 [1.35;2.15]), retinopathy (1.30 [1.02;1.65]), use of automated insulin delivery systems (1.53 [1.06;2.21]) and MSDs. MSDs were associated with reduced global quality of life (0.97 [0.95;0.98]). MSDs were not associated with HbA1c, social vulnerability or physical activity. Conclusion: We have shown that MSDs are found in 1 in 3 people with T1DM. They are associated with several lifestyle factors, diabetes complications and the use of automated insulin delivery systems. MSDs should be considered in the T1DM assessment to optimize quality of life.
AB - Background: Musculoskeletal disorders (MSDs) are common, but overlooked, complications of type 1 diabetes mellitus (T1DM). This study aims to describe MSD phenotypes (clinical, lifestyle, socio-economic) in adults with T1DM. Methods: We analyzed adult participants in the SFDT1 cohort study. We assessed the following MSDs: stress fractures, non-traumatic upper-limb disorders, and entrapment syndromes. We performed a cross-sectional analysis of the association between MSDs and various factors. After applying multiple imputations for missing data, we computed logistic regression models with progressive adjustments on confounding factors. Results: Of 1832 participants (53 % men, median age 38 (IQR 22) years), 34 % reported at least one personal history of MSD: 8 % for stress fractures, 24 % for upper-limb disorders and 15 % for entrapment syndromes. A higher prevalence of MSDs was found in women, with aging and with diabetes duration. In a fully adjusted model, we observed a positive association between current smoking (OR [95 %CI] = 1.50 [1.14;1.97]), non-excessive alcohol consumption (1.45 [1.14;1.85]), neuropathy (1.70 [1.35;2.15]), retinopathy (1.30 [1.02;1.65]), use of automated insulin delivery systems (1.53 [1.06;2.21]) and MSDs. MSDs were associated with reduced global quality of life (0.97 [0.95;0.98]). MSDs were not associated with HbA1c, social vulnerability or physical activity. Conclusion: We have shown that MSDs are found in 1 in 3 people with T1DM. They are associated with several lifestyle factors, diabetes complications and the use of automated insulin delivery systems. MSDs should be considered in the T1DM assessment to optimize quality of life.
KW - Diabetes complications
KW - Diabetic neuropathy
KW - Entrapment syndromes
KW - Fractures
KW - Musculoskeletal disorders
KW - Type 1 diabetes
KW - Upper-limb disorders
KW - Prevalence
KW - Cross-Sectional Studies
KW - France/epidemiology
KW - Humans
KW - Middle Aged
KW - Musculoskeletal Diseases/epidemiology
KW - Male
KW - Glycemic Control
KW - Diabetes Mellitus, Type 1/complications
KW - Young Adult
KW - Phenotype
KW - Blood Glucose/analysis
KW - Quality of Life
KW - Female
KW - Adult
KW - Cohort Studies
UR - http://www.scopus.com/inward/record.url?scp=105003820015&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/40280481/
U2 - 10.1016/j.diabet.2025.101647
DO - 10.1016/j.diabet.2025.101647
M3 - Article
C2 - 40280481
AN - SCOPUS:105003820015
SN - 1262-3636
VL - 51
JO - Diabetes and Metabolism
JF - Diabetes and Metabolism
IS - 4
M1 - 101647
ER -